Cited 41 times in

Nivolumab in NSCLC: latest evidence and clinical potential

Authors
 Raghav Sundar ; Byoung-Chul Cho ; Ross A. Soo ; Julie R. Brahmer 
Citation
 Therapeutic Advances in Medical Oncology, Vol.7(2) : 85~96, 2015 
Journal Title
 Therapeutic Advances in Medical Oncology 
ISSN
 1758-8340 
Issue Date
2015
Abstract
New insight on the interaction between the immune system and tumor has identified the programmed death-1/programmed death-1 ligand pathway to be a key player in evading host immune response. The immune checkpoint modulator, nivolumab (BMS-936558/ONO-4538), is the first PD-1 inhibitor to gain regulatory approval, for the treatment of patients with unresectable melanoma. This review will discuss results from early phase studies of nivolumab in solid tumors including non-small cell lung cancer (NSCLC) as well as studies of nivolumab in combination with chemotherapy, other immune modulators and molecular targeted therapy in patients with NSCLC.
URI
http://ir.ymlib.yonsei.ac.kr/handle/22282913/140780
DOI
10.1177/1758834014567470
Appears in Collections:
1. 연구논문 > 1. College of Medicine > Dept. of Internal Medicine
Yonsei Authors
사서에게 알리기
  feedback
Link
 http://tam.sagepub.com/content/7/2/85.abstract
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse